Severity of COVID-19 in Cancer patients versus patients without Cancer: A Propensity Score Matching Analysis

Chao Liu1,2#, Kai Wang3#, Luyuan Li4#, Qingquan Lv5, Yumei Liu6, Tian Hu6, Jonathan C. Trent4,6, Bing Sun7# and Qinyong Hu1#

1. Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
2. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
3. Department of Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
4. Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, USA.
5. Department of Medical Affairs, Wuhan Hankou Hospital, Wuhan, China.
6. Department of Respiratory Medicine, Wuhan Hankou Hospital, Wuhan, China.
7. Department of Radiation Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.

#These authors contributed equally to this work.

Corresponding authors: Qinyong Hu, Renmin Hospital of Wuhan University, No 99 Zhang Road, Wuchang District, Wuhan 430060, China. E-mail: rm001223@whu.edu.cn; Bing Sun, the Fifth Medical Center, Chinese PLA General Hospital, No. 8 Dongda Street, Fengtai District, Beijing 100071, China. E-mail: sunice116@163.com; and Jonathan C. Trent, Sylvester Comprehensive Cancer Center, University of Miami Health System, 1120 NW 14th St, Suite 610F, Miami, FL 33136, USA. E-mail: jtrent@med.miami.edu.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Received: 2020.10.08; Accepted: 2021.02.15; Published: 2021.04.24

Abstract

Purpose: Data are extremely limited with regards to the impact of COVID-19 on cancer patients. Our study explored the distinct clinical features of COVID-19 patients with cancer.

Experimental Design: 189 COVID-19 patients, including 16 cancer patients and 173 patients without cancer, were recruited. Propensity score 1:4 matching (PSM) was performed between cancer patients and patients without cancer based on age, gender and comorbidities. Survival was calculated by the Kaplan-Meier method and the difference was compared by the log-rank test.

Results: PSM analysis yielded 16 cancer patients and 64 propensity score-matched patients without cancer. Compared to patients without cancer, cancer patients tended to have leukopenia and elevated high-sensitivity C-reactive protein (hs-CRP) and procalcitonin. For those with critical COVID-19, cancer patients had an inferior survival than those without cancer. Also, cancer patients with severe/critical COVID-19 tended to be male and present with low SpO2 and albumin, and high hs-CRP, lactate dehydrogenase and blood urea nitrogen on admission compared to those with mild COVID-19. In terms of risk factors, recent cancer diagnosis (within 1 year of onset of COVID-19) and anti-tumor treatment within 3 months of COVID-19 diagnosis were associated with inferior survival.

Conclusions: We found COVID-19 patients with cancer have distinct clinical features as compared to patients without cancer. Importantly, cancer patients with critical COVID-19 were found to have poorer outcomes compared to those without cancer. In the cancer cohort, patients with severe/critical COVID-19 presented with a distinct clinical profile from those with mild COVID-19; short cancer history and recent anti-cancer treatment were associated with inferior survival.

Key words: COVID-19, clinical characteristics, survival, propensity score matching, cancer

Introduction

The coronavirus disease 2019 (COVID-19) outbreak first emerged in December 2019, and has since spread globally. Subsequently, this resulted in a declaration of public health emergency of international concern on 30 January 2020 and was recognized as a pandemic on 11 March 2020. The clinical manifestation of COVID-19 range from asymptomatic infections to severe viral pneumonia, acute respiratory distress syndrome (ARDS) and death [1]. A novel enveloped RNA coronavirus, now referred to as severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has been identified as the...
cancer patients, in terms of laboratory features, COVID-19. Our study addressed the questions of if cancer history were associated with prognosis of outcomes. Also, we investigated whether cancer treatment and duration of disease, including demographic and clinical characteristics, radiological and laboratory findings as well as treatment and outcomes. In addition, we reviewed independently by two physicians (KW and CL). Specifically, the data include patient-identified gender, age, symptoms, comorbidities, vital signs, coagulation and routine blood test, hepatic and renal function test, chest CT scans, treatments (antibiotic, antiviral, oxygen therapy, immunomodulators and glucocorticoids), and clinical outcomes (discharged or dead). Primary cancer characteristics (cancer type and history) and detailed treatment information (surgery, radiotherapy, chemotherapy, and targeted therapy) were obtained from patients’ past medical records.

**Definition**

The duration of COVID-19 was defined as the time interval between onset of symptoms and outcome (death or discharge from hospital). The clinical severity of COVID-19 was defined based on the criteria as described in the 6.0 version of Chinese management guideline for COVID-19, and patients were classified into mild (non-pneumonia and mild pneumonia), severe ($S_{PO2} \leq 93\%$, or respiratory frequency $\geq 30$/min, or dyspnea, or lung infiltrates >
50% within 24 to 48 hours, or PaO₂/FiO₂ ≤ 300), or critical (multiple organ dysfunction or failure, or septic shock, or respiratory failure), accordingly.

Statistical analysis
Categorical variables were presented as frequencies with percentages and compared by χ² or Fisher’s exact test. Laboratory findings, SrO₂ (%) and respiratory and pulse rates were categorized based on the corresponding cut-off values for a normal range. Kaplan-Meier analysis and log-rank test were used to evaluated patients’ survival and the differences between groups, respectively. All statistical analyses were performed using R (version 3.0.2) or SPSS 20.0 software (SPSS Inc, Chicago, IL), and a p value < .05 was considered statistically significant.

Results
Patient characteristics
We recruited a total of 189 patients with COVID-19 admitted in Wuhan Hankou Hospital between 5 January 2020 and 21 February 2020, comprising 16 cancer patients (CP) and 173 patients without cancer (PWC). Unbalanced covariates such as age, gender, and comorbidities were observed between CP and PWC groups. A propensity match was then performed, and 16 CP were matched 1:4 with 64 PWC. After matching, covariates were well balanced with no significant differences across two groups (Table 1).

Data including demographics, clinical characteristics, treatments and outcomes were shown in Table 1. Briefly, in the CP group, most were female (68.8%) and older than 60 (68.8%). The most common comorbidities were hypertension (56.3%), diabetes (25.0%) and coronary heart disease (18.8%). The most common presenting symptoms were fever (93.8%), cough (62.5%) and fatigue (56.3%). In terms of laboratory findings, patients most often had lower levels of albumin (56.3%), lymphocyte count (56.3%) and white blood cell count (43.8%), and higher levels of hs-CRP (87.5%), procalcitonin (75%) and lactate dehydrogenase (LDH) (62.5%). In terms of treatment, antibiotic therapy (68.8%) was most frequently administered, followed by antiviral therapy (68.8%) and immunomodulator (50%). In the PWC group, half were female (50.0%) and over half were older than 60 (62.5%). The top 3 common comorbidities were hypertension (43.8%), diabetes (15.6%) and coronary heart disease (12.5%). The top 3 presenting symptoms were fever (78.1%), cough (71.9%) and shortness of breath (37.5%). Patients most often had lower levels of albumin (57.8%), total protein (32.8%) and lymphocyte count (32.8%), and higher levels of hs-CRP (57.8%), procalcitonin (46.9%) and LDH (43.8%). Patients were most frequently given antibiotic therapy (84.4%), followed by antiviral therapy (46.9%) and glucocorticoid (46.9%).

Table 1. Demographics, clinical characteristics, treatments and outcome of CP and PWC with COVID-19

| Characteristic | Patients, No. (%) | p value* (unmatched comparison) | p value* (matched comparison) |
|----------------|-------------------|---------------------------------|-------------------------------|
|                | PWC before matching (n=173) | PWC after matching (n=64) | CP (n=16) |                |
| Age, >60y      | 89 (51.4)          | 40 (62.5)                       | 11 (68.8) | 0.185 | 0.642 |
| Female         | 78 (54.1)          | 32 (50.0)                       | 11 (68.8) | 0.070 | 0.263 |
| Comorbidities  |                   |                                 |                  |                |
| Coronary heart disease | 12 (6.9) | 8 (12.5) | 3 (18.8) | 0.120 | 0.685 |
| Diabetes       | 24 (13.9)          | 10 (15.6)                       | 4 (25.0) | 0.264 | 0.463 |
| Hypertension   | 59 (34.1)          | 28 (43.8)                       | 9 (56.3) | 0.045 | 0.412 |
| Cerebrovascular disease | 8 (4.6) | 3 (4.7) | 1 (6.3) | 0.557 | 1.000 |
| Chronic obstructive pulmonary disease | 6 (3.5) | 1 (1.6) | 0 (0.0) | 1.000 | 0.577 |
| Chronic liver disease | 4 (2.3) | 2 (3.1) | 1 (6.3) | 0.361 | 0.493 |
| Renal disease  | 5 (2.9)            | 3 (4.7)                         | 1 (6.3) | 0.416 | 1.000 |
| Signs and symptoms |           |                                 |                  |                |
| Fever           | 142 (82.1)         | 50 (78.1)                       | 15 (93.8) | 0.316 | 0.281 |
| Cough           | 125 (72.3)         | 46 (71.9)                       | 10 (62.5) | 0.390 | 0.545 |
| Shortness of breath | 43 (24.9) | 13 (20.3) | 3 (18.8) | 0.765 | 1.000 |
| Shortness of breath | 69 (39.9) | 24 (37.5) | 7 (43.8) | 0.763 | 0.776 |
| Diarrhea        | 13 (7.5)           | 4 (6.3)                         | 0 (0.0) | 0.607 | 0.579 |
| Nausea or vomiting | 4 (2.3) | 1 (1.6) | 0 (0.0) | 1.000 | 1.000 |
| Fatigue         | 62 (35.8)          | 20 (31.3)                       | 9 (56.3) | 0.107 | 0.083 |
| Anorexia        | 23 (13.3)          | 3 (4.7)                         | 3 (18.8) | 0.466 | 0.091 |
| Headache        | 13 (7.2)           | 1 (1.6)                         | 0 (0.0) | 1.000 | 0.260 |
| Urticaria       | 4 (2.3)            | 1 (1.6)                         | 0 (0.0) | 1.000 | 0.083 |
| Sore throat     | 4 (2.3)            | 2 (3.1)                         | 1 (6.3) | 0.361 | 0.493 |
| Respiratory rate, > 20 times/min | 64 (37.0) | 17 (26.6) | 6 (37.5) | 0.968 | 0.537 |
| Pulse rate, > 90 bpm | 58 (33.5) | 15 (23.0) | 4 (25.0) | 0.487 | 0.736 |
| So₂(%) > 93%    | 53 (28.9)          | 21 (32.8)                       | 5 (31.3) | 0.782 | 0.905 |
| CO₂ CP         | 20 (11.6)          | 10 (15.6)                       | 2 (12.5) | 1.000 | 1.000 |
| > 29 mmol/L    |                 |                                 |                  |                |
| CT findings (Bilateral) | 149 (86.1) | 56 (87.5) | 15 (93.8) | 0.700 | 0.679 |
| Laboratory Findings |           |                                 |                  |                |
| White blood cell count, < 4×10⁹/L | 35 (20.2) | 10 (15.6) | 7 (43.8) | 0.053 | 0.035 |
| Lymphocyte count, < 0.8×10⁹/L | 64 (37.0) | 21 (32.8) | 9 (56.3) | 0.130 | 0.083 |
| Platelet count, < 100×10⁹/L | 8 (4.6) | 3 (4.7) | 2 (12.5) | 0.203 | 0.260 |
| D-dimer, > 0.5 ug/ml | 54 (31.2) | 25 (39.1) | 8 (50.0) | 0.126 | 0.427 |
| Hypersensitive C-reactive protein, > 6 mg/L | 87 (50.5) | 30 (46.9) | 12 (75.0) | 0.058 | 0.044 |
| Procalcitonin, > 0.05 ng/mL | 74 (42.8) | 28 (43.8) | 10 (62.5) | 0.129 | 0.179 |
| Lactate dehydrogenase, > 250 U/L | 36 (20.8) | 8 (12.5) | 3 (18.8) | 1.000 | 0.685 |
| Alkaline phosphatase, > 140 U/L | 47 (27.2) | 11 (17.2) | 4 (25.0) | 1.000 | 0.485 |
| r-glutamyl transferase, > 60 U/L | 6 (3.5) | 2 (3.1) | 0 (0.0) | 1.000 | 1.000 |

http://www.jcancer.org
Comparison in clinical features between COVID-19 CP and PWC

With respect to symptoms on presentation, compared with PWC, CP tended to have fatigue and anorexia (56.3% vs. 31.3%, \( p = 0.083; 18.8\% \text{ vs. } 4.7\%, \ p = 0.091, \) respectively), but the prevalence of other symptoms, including fever, cough, sputum, short of breath, diarrhea, nausea or vomiting, headache, myalgia, and sore throat was similar between two groups (all \( p > 0.05\)). Laboratory findings on admission showed CP tended to have leukopenia (43.8\% vs. 15.6\%, \( p = 0.035\)), lymphopenia (56.3\% vs. 32.8\%, \( p = 0.083\)), and elevated hs-CRP (87.5\% vs. 57.8\%, \( p = 0.027\)) and procalcitonin (75.0\% vs. 46.9\%, \( p = 0.044\)) than PWC (Table 1). There were no significant differences in other laboratory markers such as indicators of infection and hepatorenal function between CP and PWC. In terms of treatments, antiviral therapy appeared to be more frequently given to CP than PWC (68.8\% vs. 46.9\%, \( p = 0.164\)), but other treatments, including antibiotic therapy, immunomodulator, glucocorticoids, and oxygen therapy, were administered to patients with no preference (all \( p > 0.05\)).

**Comparison in COVID-19 clinical outcomes between CP and PWC**

Overall, CP had a trend toward an inferior survival (\( p = 0.197\)) with a higher fatality ratio (18.8\% vs. 7.8\%, \( p = 0.194\)) and slightly longer disease duration (29.5 vs. 26.0 days, \( p = 0.879\)) than PWC (Figure 1A). Importantly, for patients with critical COVID-19, CP showed a significantly inferior survival (\( p = 0.013\)) with a trend toward a higher fatality ratio (100.0\% vs. 41.7\%, \( p = 0.200\)) and shorter disease duration compared to PWC (15.0 vs. 28.5 days, \( p = 0.110, \) Figure 1B), suggesting CP with critical COVID-19 tend to deteriorate rapidly and die during hospitalization.

---

**Table 1.** Comparison in clinical features between COVID-19 CP and PWC.

| Characteristic | Patients, No. (%) | \( p \) value* | \( p \) value* |
|---------------|-------------------|---------------|---------------|
| > 8.8 mmol/L  | Creatinine, > 120 umol/L | 18 (10.4) 6 (9.4) 3 (18.8) 0.395 | 0.373 |
| Uric acid, > 440 umol/L | 14 (8.1) 3 (4.7) 2 (12.5) 0.630 | 0.260 |

**A** Comparisons of survival, fatality ratio and disease duration between COVID-19 CP and PWC (A); critical COVID-19 CP and PWC (B). CP, cancer patients; PWC, patients without cancer.

**Figure 1.** Comparisons of survival, fatality ratio and disease duration between COVID-19 CP and PWC (A); critical COVID-19 CP and PWC (B). CP, cancer patients; PWC, patients without cancer.
Table 2. The differences of demographics, clinical characteristics, treatments and outcome between CP with mild and severe/critical COVID-19

| Characteristic                        | CP, No. (%) | p value |
|--------------------------------------|-------------|---------|
|                                     | Mild (n = 10) | Severe/Critical (n = 6) |
| Age, > 60y                           | 5 (50.0)     | 6 (100.0)     | 0.059 |
| Female                               | 9 (90.0)     | 2 (33.3)     | 0.036 |
| Comorbidities                        |             |           |          |
| Coronary heart disease               | 3 (30.0)     | 1 (16.7)     | 1.000 |
| Diabetes                             | 2 (20.0)     | 2 (33.3)     | 0.604 |
| Hypertension                         | 6 (60.0)     | 3 (50.0)     | 1.000 |
| Cerebrovascular disease              | 1 (10.0)     | 0 (0.0)     | 1.000 |
| Chronic obstructive pulmonary disease| 0 (0.0)      | 0 (0.0)     | /      |
| Chronic liver disease                | 0 (0.0)      | 1 (16.7)     | 0.375 |
| Renal disease                        | 1 (10.0)     | 0 (0.0)     | 1.000 |
| Signs and symptoms                   |             |           |          |
| Fever                                | 9 (90.0)     | 6 (100.0)     | 1.000 |
| Cough                                | 7 (70.0)     | 3 (50.0)     | 0.607 |
| Sputum                               | 2 (20.0)     | 1 (16.7)     | 1.000 |
| Shortness of breath                  | 4 (40.0)     | 3 (50.0)     | 1.000 |
| Diarrhea                             | 0 (0.0)      | 0 (0.0)     | /      |
| Nausea or vomiting                   | 0 (0.0)      | 0 (0.0)     | /      |
| Fatigue                              | 5 (50.0)     | 4 (66.7)     | 0.633 |
| Anorexia                             | 1 (10.0)     | 2 (33.3)     | 0.518 |
| Headache                             | 0 (0.0)      | 0 (0.0)     | /      |
| Myalgia                              | 2 (20.0)     | 0 (0.0)     | 0.500 |
| Sore throat                          | 0 (0.0)      | 1 (16.7)     | 0.375 |
| Respiratory rate, > 20 times/min     | 4 (40.0)     | 2 (33.3)     | 1.000 |
| Pulse rate, > 90 bpm                 | 3 (30.0)     | 1 (16.7)     | 1.000 |
| SgO2(<), < 93%                       | 0 (0.0)      | 5 (83.3)     | 0.001 |
| CO2 CP, > 9 mmol/L                   | 2 (20.0)     | 0 (0.0)     | 0.500 |
| CT findings (Bilateral)              | 9 (90.0)     | 6 (100.0)     | 1.000 |
| Laboratory Findings                  |             |           |          |
| White blood count cell, < 4×10^9/L   | 5 (50.0)     | 2 (33.3)     | 0.633 |
| Lymphocyte count, < 0.8×10^9/L       | 4 (40.0)     | 5 (83.3)     | 0.145 |
| Platelet count, < 100×10^9/L         | 1 (10.0)     | 1 (16.7)     | 1.000 |
| D-dimer, > 0.5 ug/ml                 | 3 (30.0)     | 4 (66.7)     | 0.302 |
| Hypersensitive C-reactive protein, > 6 mg/L | 4 (40.0)     | 6 (100.0)     | 0.034 |
| Procalcitonin, > 0.05 ng/mL          | 6 (60.0)     | 5 (83.3)     | 0.588 |
| Lactate dehydrogenase, > 250 U/L     | 2 (20.0)     | 5 (83.3)     | 0.035 |
| Alanine aminotransferase, > 40 U/L   | 1 (10.0)     | 2 (33.3)     | 0.518 |
| Aspartate aminotransferase, > 40 U/L | 2 (20.0)     | 2 (33.3)     | 0.604 |
| Alkaline phosphatase, > 140 U/L      | 0 (0.0)      | 0 (0.0)     | /      |
| r-glutamy transferase, > 60 U/L      | 0 (0.0)      | 2 (33.3)     | 0.125 |
| Total protein, < 60 g/L              | 3 (30.0)     | 3 (50.0)     | 0.607 |
| Albumin, < 34 g/L                    | 3 (30.0)     | 6 (100.0)     | 0.011 |
| Globulin, < 26 g/L                   | 1 (10.0)     | 0 (0.0)     | 1.000 |
| Blood urea nitrogen, > 9.5 mmol/L    | 0 (0.0)      | 3 (50.0)     | 0.036 |
| Creatinine, > 120 umol/L             | 1 (10.0)     | 2 (33.3)     | 0.518 |
| Uric acid, > 440 umol/L              | 1 (10.0)     | 1 (16.7)     | 1.000 |
| Treatments                           |             |           |          |
| Antibiotic therapy                   | 7 (70.0)     | 6 (100.0)     | 0.250 |
| Antiviral therapy                    | 6 (60.0)     | 5 (83.3)     | 0.588 |
| Immunomodulator                      | 5 (50.0)     | 3 (50.0)     | 1.000 |
| Systemic glucocorticoids             | 1 (10.0)     | 4 (66.7)     | 0.036 |
| Oxygen therapy                       | 8 (80.0)     | 6 (100.0)     | 0.500 |
| Nasal cannula                        | 7 (70.0)     | 2 (33.3)     | 0.362 |
| Mask oxygen                          | 1 (10.0)     | 2 (33.3)     | 0.620 |
| Mechanical ventilation               | 0 (0.0)      | 2 (33.3)     | 0.125 |
| Clinical outcome (died)              | 0 (0.0)      | 3 (50.0)     | 0.036 |

Abbreviations: CP, cancer patients.

For patients with mild COVID-19, all were alive and discharged (Figure 2A-B), but CP showed a trend toward a longer disease duration than PWC (median, 33.0 vs. 25.0 days, p = 0.187, Figure 2C), suggesting CP with mild COVID-19 tend to have a longer recovery period. Consistent with the finding in patients with critical COVID-19, for patients with severe/critical COVID-19, CP had a trend toward a higher fatality ratio (50.0% vs. 20.8%, p = 0.30) with a shorter disease duration (median, 16.0 vs. 34.5 days, p = 0.112) than PWC (Figure 2C), suggesting CP with severe/critical COVID-19 tend to deteriorate rapidly and die during hospitalization. For patients with severe COVID-19, CP tend to have a slightly shorter disease duration (median, 33 vs. 38.5 days, p = 0.556) than PWC (Supplementary Figure 1).

Comparison in clinical features between CP with mild and severe/critical COVID-19

According to the disease severity criteria for COVID-19 as described previously, among the 16 CP, 10 (62.5%) were classified into mild disease group while the rest 6 (37.5%) were classified into severe/critical disease group. The clinical characteristics of CP in both groups were shown in Table 2. Compared to those with mild disease, CP with severe/critical disease were significantly more likely to be male (66.7% vs. 10.0%, p = 0.036) and present with abnormally low levels of SrO2 (83.3% vs. 0.0%, p = 0.001) and albumin (100.0% vs. 30.0%, p = 0.011), and also high levels of hs-CRP (100.0% vs. 40.0%, p = 0.034), LDH (83.3% vs. 20.0%, p = 0.035) and BUN (50.0% vs. 0.0%, p = 0.036) on admission. Although not statistically significant, there was a trend for the severe COVID-19 CP to be older than 60 (100.0% vs.50.0%, p = 0.059). Also, compared to those with mild disease, CP with severe/critical disease were more often given glucocorticoids (66.7% vs. 10.0%, p = 0.036), but no significant differences with respect to comorbidities, signs and symptoms were appreciated between two subgroups of CP. Moreover, as expected, CP with severe/critical disease had a higher fatality ratio (50.0% vs. 0.0%, p = 0.036, Table 2) and shorter disease duration (median, 16.0 vs. 33.0 days, Figure 2C) than those with mild disease. The short disease duration of CP with severe/critical disease is attributed to the rapid patient deterioration during hospitalization. In addition, we also compared clinical features between PWC with mild and severe/critical COVID-19; details were shown in Supplementary Table 1.

Tumor characteristics and risk factors for COVID-19 CP

The primary tumor characteristics of 16 CP with COVID-19 were shown in Table 3. Colorectal cancer was the most frequent cancer type (5, 31.2%), followed by lung cancer (2, 12.5%), lymphoma (2, 12.5%), and cervical cancer (2, 12.5%) (Table 3). 13 (81.3%) patients
were diagnosed with cancer > 1 year and 12 (75.0%) patients received antitumor treatment > 3 months prior to infection. The prevalence of severe/critical disease in patients with cancer history ≤ 1 year or anti-cancer treatment ≤ 3 months prior to infection was higher than those with cancer history >1 year or anti-tumor treatment >3 months prior to infection, respectively \( (p = 0.036, p = 0.003, \text{respectively}) \). In terms of outcome, patients with cancer history ≤ 1 year or anti-tumor treatment ≤ 3 months prior to infection had worse survival \( (p = 0.021, p < 0.001, \text{respectively}) \) with higher fatality ratios (66.7% vs. 7.7%, \( p = 0.071; 75\% \text{ vs. } 0\%, p = 0.007, \text{Figure 3}) than patients with cancer history >1 year or anti-tumor treatment > 3 months prior to infection, respectively.

**Discussion**

The rapidly expanding coronavirus pandemic has affected all areas of daily life, including medical care. Immunosuppression from malignant disease or its treatment renders cancer patients particularly susceptible to infections [16]. Therefore, the clinicians need to weigh the risks of death and morbidity from the infection against the magnitude of benefit of intended cancer therapies. Our study aimed to understand the impact of COVID-19 on cancer patients, which will benefit the oncology society in guiding cancer care delivery amid this pandemic. We found that cancer patients with COVID-19 overall tend to have more specific onset symptoms such as anorexia and fatigue, leucopenia, lymphopenia, elevated hs-CRP and procalcitonin, longer disease duration and poorer outcomes compared to those without cancer. Importantly, we observed that cancer patients with critical disease have worse prognosis than their controls without cancer. Moreover, our study also showed short cancer history and recent anti-tumor treatments are associated with poor COVID-19 clinical outcomes.

Figure 2. Survival analysis of mild and severe/critical COVID-19 CP (A); PWC (B); comparison of disease duration (C). CP, cancer patients; PWC, patients without cancer.

Figure 3. Comparisons of survival and fatality ratio between patients with cancer history > 1 year and ≤ 1 year (A) or anti-cancer therapy > 3 months and ≤ 3 months (B). ** represents \( p < 0.01 \).
Limited data suggested the likelihood of a severe illness from COVID-19 is higher among patients with cancer, particularly if they recently received or are continuing to receive treatment. Several studies were conducted on cancer patients diagnosed with COVID-19 from different countries, including the People’s Republic of China, the United Kingdom, and the United States of America. These studies revealed that lung cancer, hematologic malignancy, lymphopenia, advanced age, male gender, and comorbidities were associated with greater severity of COVID-19 [17-20]. By analyzing 18 cancer patients from a nationwide cohort of 1590 COVID-19 cases, Liang et al. found compared with patients without cancer, cancer patients had a higher risk for severe clinical events (defined as invasive ventilation, ICU admission, or death) [11]. However, in their study, the comparisons were directly made based on cancer patients and patients without cancer who had unbalanced potential confounding factors such as age, gender and comorbidities, posing a concern of biased estimate. To reduce the influence of these confounding factors, we performed PSM and made pairs from COVID-19 cancer patients and patients without cancer. By analyzing 16 cancer patients and their matched 64 non-cancer controls, we observed cancer patients overall have a relatively longer disease duration (29.5 vs. 26.0 days) and higher fatality ratio (18.8% vs. 7.8%). Noteworthy, the fatality ratios for both cancer patients and patients without cancer are much higher than the reported overall CFR, 2.3% or 5.6% among cancer patients [1]. The high fatality ratios in our study can be attributed to the additive effects of other confounding factors such as age and pre-existing comorbid conditions (Table 1). Moreover, data show the CFR among critical cases of COVID-19 is dozens of times higher than overall [1]. It is expected there is an exceptionally high fatality ratio among critical cases of cancer patients as well. Indeed, we observed up to half of the cancer patients with severe/critical disease in our study progressed rapidly and ended up with death during hospitalization. Interestingly, compared to those with mild disease, we noticed cancer patients with severe/critical disease tend to be male and older, and have low level of SrO2, high levels of hs-CPR and LDH, and abnormal levels of markers of poor hepatorenal function on admission (Table 2). We believe more distinctions between these two groups will be detected as sample size increases. Furthermore, given the quite different clinical characteristics of COVID-19 patients with mild and severe/critical COVID-19 [7, 21], we further investigated the respective impact of COVID-19 on subgroups of cancer patients. Intriguingly, we observed cancer patients with mild disease present with similar clinical features to their controls without cancer except a longer disease duration which is indicative of slower recovery for cancer patients due to their compromised immune system. In contrast, cancer patients with critical disease have an inferior survival with a higher fatality ratio (100.0% vs. 41.7%) and shorter disease duration (15.0 vs. 28.5 days) compared to their controls without cancer, suggesting that cancer patients have a greater tendency to deteriorate fast and die from critical COVID-19. Our evidence here warrants an escalated level of care to this group of cancer patients.

Delivering cancer care is challenging during this COVID-19 crisis, and data pertaining to therapeutic perspective are urgently needed to help us weigh the competing risks of death or serious complications from cancer versus COVID-19. Zhang et al. retrospectively studied clinical features of 28 cancer patients with COVID-19. They found receiving anti-tumor treatment 14 days prior to infection significantly increased the risk of severe events (defined as the admission to ICU, or mechanical ventilation, or death) [10]. However, their study is mainly based on severe cases, with over half of patients ending up with severe outcomes. Thus, their patient sample is not well representative of the whole cancer population with COVID-19. Given that 14-day is a relatively narrow interval which suits only a small portion of cancer patients, we extended this interval to 3-month in our study. Consistent with their study, we found patients receiving anti-cancer treatments (chemotherapy, surgery or targeted therapy) within 3 months prior to infection have an inferior survival  

Table 3. Cancer characteristics in 16 COVID-19 CP  

| Characteristic | CP, No. (%) | Total (n = 16) | Mild (n = 10) | Severe (n = 3) | Critical (n = 3) | p value |
|---------------|------------|---------------|--------------|---------------|----------------|--------|
| Cancer type   |            |               |              |               |                |        |
| Nasopharyngeal cancer | 1 (6.3) | 1 (10.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.955 |
| Thyroid cancer | 1 (6.3) | 1 (10.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |        |
| Breast cancer  | 1 (6.3) | 1 (10.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |        |
| Lung cancer    | 2 (12.5) | 1 (10.0) | 1 (33.3) | 0 (0.0) |       |        |
| Colorectal cancer | 5 (31.3) | 2 (20.0) | 2 (66.7) | 1 (33.3) |       |        |
| Gastric cancer | 1 (6.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (33.3) |        |
| Lymphoma      | 2 (12.5) | 1 (10.0) | 0 (0.0) | 0 (0.0) | 1 (33.3) |        |
| Cervical cancer | 2 (12.5) | 2 (20.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |        |
| Skin cancer   | 1 (6.3) | 1 (10.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |        |
| Cancer history |            |               |              |               |                |        |
| > 1y          | 13 (81.3) | 10 (100.0) | 2 (66.7) | 1 (33.3) | 0.036 |
| ≤ 1y          | 3 (18.8) | 0 (0.0) | 1 (33.3) | 2 (66.7) |       |        |
| Cancer therapy prior to COVID-19 |            |               |              |               |                |        |
| > 3m          | 12 (75.0) | 10 (100.0) | 2 (66.7) | 0 (0.0) | 0.003 |
| ≤ 3m          | 4 (25.0) | 0 (0.0) | 1 (33.3) | 3 (100.0) |       |        |
| Cancer therapy within 3 months |            |               |              |               |                |        |
| Surgery and chemotherapy | 1 (6.3) | 0 (0.0) | 0 (0.0) | 1 (33.3) | 1.000 |
| Chemotherapy  | 2 (12.5) | 0 (0.0) | 1 (33.3) | 1 (33.3) |       |        |
| Targeted therapy | 1 (6.3) | 0 (0.0) | 0 (0.0) | 1 (33.3) |       |        |

Abbreviations: CP, cancer patients.
with a higher fatality ratio than those receiving anti-cancer treatment more than 3 months prior to infection (75% vs. 0%). These findings suggest patients undergoing active cancer treatment have substantially increased risk of death from COVID-19. Thus, a delay of certain treatments will be more beneficial for patients with certain cancers that has low risk of progression in the midst of pandemic. We next explored whether long-term cancer survivors are also at increased risk of death from COVID-19. Our data demonstrated that patients with a cancer history less than 1 year have an inferior survival with a higher fatality ratio than those with a cancer history more than 1 year (66.7% vs. 7.7%). It should be noted the latter fatality ratio is close to that among patients without cancer (7.7% vs. 7.8%), indicating long-term cancer survivors may have a comparable risk of COVID-19 related lethality.

Through the use of COVID-19 patients without cancer as controls, novel and potentially useful clinical characteristics of cancer patients with COVID-19 were unveiled. By performing PSM, we balanced potential confounding covariates across groups of patients, and thus obtained an unbiased estimate of the impact of COVID-19 on cancer patients. In the future, it may be possible to identify cancer patients at risk for severe/critical COVID-19 using criteria including low SpO2 and albumin as well as high hs-CRP, LDH and BUN. Moreover, cancer patients diagnosed in the past year or treated with chemotherapy in the past 3 months and who may potentially be exposed to COVID-19 should be approached with strict PPE and physical distancing. However, this retrospective analysis has several limitations. This study was limited on a small sample size with heterogeneity such as various cancer types and COVID-19 treatment strategies. Due to the small sample size, some associations were inferred from the observed data trends instead of statistical significances. Thus, the key factors associated with severe/critical COVID-19 in cancer patients and other inferred associations should be verified in a larger study or a meta-analysis.

**Supplementary Material**

Supplementary figures and tables.  
http://www.jcancer.org/v12p3558s1.pdf

**Acknowledgments**

This work was supported by National Natural Science Foundation of China (No. 81670144).

**Competing Interests**

The authors have declared that no competing interest exists.

**References**

1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. Jama. 2020; 323: 1239-42.
2. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. The New England journal of medicine. 2020; 382: 727-33.
3. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infectious disease. 2020; 20: 533-34.
4. de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nature Review Microbiology. 2016; 14: 523-34.
5. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020; 395: 689-97.
6. Verity R, Okell L, Dorliguitt I, et al. Estimates of the. severity of coronavirus disease 2019: a model-based analysis. The Lancet Infectious diseases. 2020; 20: 669-77.
7. Luo J, Rizvi H, Preeshagul IR, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. The New England journal of medicine. 2020; 382: 1708-20.
8. Team CC-R. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020. MMWR Morbidity and mortality weekly report. 2020; 69: 382-6.
9. Yu J, Ouyang W, Chua MLK, et al. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA oncology. 2020; 6: 1108-10.
10. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Annals of oncology : official journal of the European Society for Medical Oncology. 2020; 31: 894-901.
11. Liang WH, Guan WJ, Chen RC, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21: 335-7.
12. [Internet] WHO. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases Interim guidance 17 January 2020. https://apps.who.int/iris/bitstream/handle/10665/330857/WHO-2019-nCoV-SurveillanceGuideance-2020.3-eng.pdf.
13. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). 2020; 395: 1054-62.
14. Du RH, Liang LR, Yang CQ, et al. Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prosp ective Cohort Study. The European respiratory journal. 2020; 55.
15. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA internal medicine. 2020; 180: 934-43.
16. Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. Lancet Oncology. 2009; 10: 589-97.
17. Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020; 395: 1054-62.
18. Lee LY, Cazier JB, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020; 21(10): 1309-1316.
19. Garassino MC, Whisnant JG, Huang LC, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020; 21(7):914-922.
20. Luo J, Rizvi H, Preeshagul IR, et al. COVID-19 in patients with lung cancer. Ann Oncol. 2020; 31(10):1386-1396.
21. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama. 2020; 180: 934-43.